Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

577.21 +35.32 (+6.52%)
Delayed Quote Updated: 3:45 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,365,646
Open 557.53
Bid (Size) 577.00 (160)
Ask (Size) 577.42 (120)
Prev. Close 541.89
Today's Range 556.76 - 585.79
52wk Range 409.07 - 609.35
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ... 
Via StockStory
Topics Intellectual Property
News headline image
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory

Performance

YTD
+16.2%
+16.2%
1 Month
+13.1%
+13.1%
3 Month
+5.5%
+5.5%
6 Month
+1.2%
+1.2%
1 Year
+37.7%
+37.7%

More News

Read More
News headline image
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
From United Therapeutics
Via Business Wire
News headline image
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
Via StockStory
Topics Intellectual Property
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗
Via Chartmill
News headline image
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions ↗
Via MarketBeat
News headline image
Why United Therapeutics (UTHR) Shares Are Falling Today
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
Via StockStory
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
Via StockStory
Topics Artificial Intelligence
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗
Via Chartmill
News headline image
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Profitable Stocks We’re Skeptical Of
Via StockStory
News headline image
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
Via StockStory
News headline image
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
Via StockStory
News headline image
United Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 577.21
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 10/01/26 03:45 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 25.91B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 26B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.